Leif R. Nelson
New technologies delivered to your inbox Subscribe
2016-372 – Mayo Clinic Researchers have discovered that microbiome associated protein 1 (MAP1)B1 is the antigen for PCA-2 autoantibodeis.
2015-347 – Mayo Clinic has developed compositions and methods for detecting soluble PD-L1
2015-311 – Mayo Clinic has discovered that HEATR1 is a novel Akt regulator and a predictor for chemoradioresistance.
2015-312 – Mayo Clinic has discovered that the Parkin protein is a mitotic regulator. Cancer cells with deficiency or mutations in Parkin have an increase in mitotic regulator expression leading to tumorigenesis and an increase in sensitivity of Pk1 and Aurora kinase inhibitors. This newly identified mechanism has revealed that Parkin mutations may be used as a biomarker for measuring the sensitivity of... Read More
2015-164 – Mayo Clinic has discovered that WSB1 can be used as a diagnostic marker for tumor metastasis and a therapeutic target.
2013-237 – Bim is a biomarker for PD-1 and PD-L1 therapies.
Methods of Treating Cancer by Using PD1 and PD-L1 inhibitors by Using Soluble PD-L1 Levels as a Biomarker
2008-042 – Mayo Clinic has patent rights claiming methods of using PD1 or PD-L1 antibodies to treat cancer by using soluble PD-L1 levels in the serum as a biomarker.
2003-132 – Mayo Clinic has patent rights claiming methods of detecting the autoantibody associated with NMO.
2004-239 – Mayo Clinic has patent rights claiming the use of PD1 and PD-L1 antibodies to treat cancer. The patent rights also include diagnostic and prognostic claims.
2002-064 – Mayo Clinic has patent rights broadly claiming the use of PD-L1 antibodies to treat cancer.
1999-098 – Mayo Clinic has patent rights broadly claiming PD-L1 antibodies along with other PD-L1 related fundamental patent claims.
2017-036 – Mayo Clinic has discovered that inhibition of stearoyl-CoA desaturase 1, SCD1 - a key enzyme fatty acid metabolism, in combination with PD1/PD-L1 inhibition enhances T cell based cancer immunotherapy.
2017-176 – Mayo Clinic has discovered that novel SCD1 inhibitors can be used to treat liver cancer.
2016-386 – Mayo Clinic has discovered the UFM1 signaling pathway as a biomarker/therapeutic target in cancer. UFM1 is an Ub-like molecule needed for ATM activation and DNA damage response. Inhibiting the pathway could sensitize cancer cells to radiation and chemotherapy.
2016-055 – Mayo Clinic has discovered the functional roles for DUB3, an ubiquitin specific protease, and CDK4/6 inhibitors, in their ability to regulate cancer metastasis. CDK4/6 inhibitors blocked triple-negative breast cancer metastasis.
2015-196 – Mayo Clinic has discovered that BET inhibitors hinder the homologous recombination process in DNA repair and that BET inhibitors sensitize tumors to PARP inhibitor treatment.
Therapeutic Modulation of the MoCo Biosynthesis Pathway to Protect Neurons and Axons from Inflammation-Induced Injury
2014-299 – Mayo Clinic has developed an innovative therapeutic strategy to use molybdenum cofactor (MoCo) to treat neurological inflammatory disease.
2014-207 – Mayo Clinic has discovered a therapeutic pathway to target PD-L1 (a.k.a. B7-H1) positive tumors. Inhibition of DNA-PKcs function restores the sensitivity of PD-L1 positive tumors to chemotherapy by two fold.
Combining Single Domain Antibody Fragments and Mass Spectrometry as a Diagnostic Test for Patients with Plasma Cell Dyscrasias
2015-146 – Mass spectra of proteins isolated using single domain antibody fragments (SDAF) with affinity for immunoglobulins are used to identify, quantitate, and establish heavy and light chain pairings of M-proteins using MALDI-TOF mass spectrometry. The invention utilizes the unique molecular mass and structure of single domain antibody fragments and the unique molecular mass distributions of heavy... Read More
2015-065 – Mass accuracy is used to measure free light chains in serum, urine, CSF and body fluid. The mass accuracy allows for direct quantitation of each kappa and lambda light chain. This technique is useful in the diagnosis and prognosis of multiple myeloma, MGUS, B-CLL, Waldenstroms macrogloblinemia, AL amyliodosis, non-secretory myeloma and for distinguishing an auto-immune response from a... Read More
2015-064 – High mass accuracy is used to measure Igs in CSF and serum. The mass accuracy allows for direct quantitation of each kappa and lambda light chain and can be used as a surrogate marker for active clonal B-cells. This method increases the accuracy of clone matching between serum and CSFand utilizes top-down mass spectrometry which allow for fragmentation patterns to be used for absolute... Read More
2014-229 – Computer modeling followed by synthesis of novel compounds and testing for stearoyl CoA desaturase 1 (SCD1) specific growth inhibition of cancer cells has led to the identification of four novel lead SCD1 inhibitors.
2013-206 – This invention has benefit over other methods since it directly quantitates the mAb without the need for interaction with the antigen. By monitoring tryptic peptides from the unique variable regions of the therapeutic mAb and comparing them to the constant regions of a non-human antibody added as an internal standard, the mAb can be measured. This method is superior to other methods using... Read More
2012-285 – A method to identify if an M-spike contains either a kappa or lambda light chain has been discovered through the use of liquid chromatography tandem mass spectrometry (LC-MS/MS).
2012-139 – In normal healty individuals, the plasma cells produce numerous immunoglobulins each with its own unique protein sequence and hence a unique mass. When examined together, the distribution of the masses forms a Gaussian distribution. Patients whom have plasma cells that overproduce immunoglobulins (M-proteins) are at risk for developing serious diseases such as multiple myeloma. Currently,... Read More
2012-062 – Broad patent claims have issued claiming methods for treating renal cell carcinoma by using SCD1 inhibitors and are available for licensing.
2013-312 – A series of novel prodrugs of K channel openers demonstrated significant intraocular pressure (IOP) lowering in normal mice and in a mouse model of glaucoma. The IOP lowering response obtained from using a K channel openers prodrug combined with other glaucoma drugs on the market seems to be somewhat synergistic
2011-184 – Methods and Materials for Assessing Responsiveness PARP Inhibitors and Platinating Agents Methods and materials have been developed for assessing responsiveness to PARP inhibitors and platinating agents by using levels of non-homogous end-joining (NHEI) pathway members to determine if cancer cells that are homologous recombination (hr) - deficient are likely to be susceptible or resistant... Read More
2011-130 – The calibration data for an accelerated contrast-enhanced MRA acquisition are acquired in the short time after contrast injection and before contrast arrival. This eliminates the separate acquisition for calibration data.
2011-021 – A method is developed for eliminating the calibration scan in SENSE-accelerated time-resolved MRA.
2011-020 – Progress of an intravenously administered contrast bolus along the peripheral vasculature is tracked in real time by generating diagnostic quality images and then using the information to cause the patient table to move so as to allow generation a high quality angiogram along the entire extent of the vasculature.
2010-152 – A device and method for MRI in-scanner imaging of chronic exertional compartment syndrome (CECS) of the lower legs has been developed and validated.
2010-026 – Accelerated MRI: A method is described for improving parallel acquisition along the longitudinal direction.
2009-235 – Using accelerated time-resolved 3-D imaging methods such as the Mayo-developed Cartesian Acquisition with Projection Reconstruction like sampling (CAPR) it is possible to generate data for both a time series of MR angiograms as well as an image of perfusion.
2009-132 – A monoclonal antibody to MDC1, a key mediator of DNA damage response.
2008-299 – A technique is described for taking images generated from an MRI acquisition done with contrast administration and converting the image data into a single image which portrays the time of arrival (TOA) of the advancing contrast bolus. The TOA image allows distinction of arterial from venous structures based on their different arrival times. The quality of the results depends on... Read More
2008-315 – Parallel imaging can be applied to further reduce acquisition times. To do so, coil sensativities have to be determined. One option is to use self-or-auto calibrated methods which in general use unaccelerated sampling in some central region of the otherwise undersampled k-space. However, the fraction of acquisition time devoted to calibration can be substantial, particularly in high... Read More
Aquaporin-4-Binding Autoantibodies in Patients with Neuromyelitis Optica Impair Glutamate Transport by Down-Regulating EAAT2
2008-303 – Materials and Methods for Treating Neuromyelitis Optics (NMO) Methods for treating NMO are claimed including the use of glulamate receptor antagonists and/or compounds that inhibit complement.
2008-136 – A method is described which provides reduction of acquisition time for 3DFT MRI. It is based on a specific way to sample k-space which is robust to undersampling. It can be used in conjunction with other methods for reduction of acquisition time.
2008-178 – A technique is described for MR imaging of an extended field of which uses a combination of multiple-fixed-station and continuously moving table acquisitions. This preserves the ability to perform acceleration techniques and also provides high time efficiency.
2008-177 – A coil array is designed for 2D acceleration in MRI for imaging an object with markedly different fields of view in the two phase encoding directions in which the coil elements in one direction have markedly different size than elements in the other direction.
2007-326 – JJ12 is a mouse monoclonal IgG antibody that was prepared against the human protein p23, a co-chaperone for the molecular chaperone protein Hsp90. p23 was isolated into balb/c mice, and hybridoma cells were made by fusion with the cell line P3NS-11-AG4-1(NS-1). JJ12 has a high affinity for p23 from humans and several other vertebrates. It is useful for the measurement of p23 by western... Read More
2007-325 – JJ6 is a mouse monoclonal IgG antibody that was prepared against the human protein p23, a co-chaperone for the molecular chaperone protein Hsp90. p23 was isolated and injected into balb/c mice, and hybridoma cells were made by fusion with the cell line P3NS-11-AG4-1 (NS-1). JJ6 has a high affinity for p23 from humans and several other vertebrates. It is useful for the measurement of p23 by... Read More
2007-324 – This is a monoclonal antibody, produced in mice, to the human protein tsp23 which has sequence similarity to the molecular co-chaperone p23.
2007-323 – This is a monoclonal antibody against GCUNC45 (General Cell UNC45) also called SMAP-1 which has sequence similarity with the SMUNC45 (Striated muscle UNC45). These are homologues of the C. elegans UNC45. This antibody is useful western blotting and imunohistochemistry.
2006-290 – Technology Description Expression of B7-H3 on the cell surface of tumor cells and tumor-associated vasculature is greatly increased in prostate and renal cancers. B7-H3 is predictive of disease progression and poor survival and is a therapeutic target for tumor cells and tumor-associated vessels by antibody directed cytotoxicity. Application B7-H3 may be a useful prognostic marker for... Read More
2006-018 – Technology Description B7-H4 is a cell surface protein whose expression on tumor cells and tumor-associated vasculature is greatly increased in renal cancers. B7-H4 expression levels on renal tumors have been shown to be a predictor of tumor aggressiveness and to increase mortality rates. B7-H4 is highly expressed on tumors and tumor-associated vasculature but not on normal tissues and... Read More
2005-127 – Antibodies to various isoforms of HP-1 and SP-1
Tandem Mass Spectrometry (MS/MS) of Thiopurine Methyltransferase (TPMT) Reaction Products in order to Quantitate TPMT Enzyme Activity
2005-017 – This invention provides methods and materials related to the measurement of TPMT enzymatic activity in biological samples. The assay involves the incubation of a cell lysate with a TPMT substrate and S-adenosyl-L-methionine (SAM), which acts as a methyl donor, and an isotopically labeled internal standard corresponding to the enzymatically produced methylation product of the TPMT substrate.... Read More
2005-015 – Software that is able to recognize internal fat within the valve and eliminate it as a diagnostic possibility.